Comparative analysis of efficacy and safety of different regimens in the treatment of AIDS-related Burkitt lymphoma:a single-center retrospective study
10.3969/j.issn.1006-7795.2025.03.005
- VernacularTitle:比较不同方案治疗艾滋病相关伯基特淋巴瘤的疗效和安全性分析:一项单中心回顾性研究
- Author:
Qinglian WANG
1
;
Ying TENG
1
;
Wenying QIAO
1
;
Jinglong CHEN
1
;
Xiaoyan DING
1
Author Information
1. 首都医科大学附属北京地坛医院肿瘤内科,北京 100015
- Publication Type:Journal Article
- Keywords:
Burkitt lymphoma;
acquired immune deficiency syndrome;
DA-EPOCH-R regimen;
modified CODOX-M/IVAC-R regimen;
efficacy and safety
- From:
Journal of Capital Medical University
2025;46(3):427-435
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of the dose-adjusted etoposide,doxorubicin and cyclophosphamide with vincristine,prednisone and rituximab without radiotherapy(DA-EPOCH-R)regimen versus the modified cyclophosphamide,vincristine,doxorubicin,high-dose methotrexate(CODOX-M/IVAC-R)regimen in the treatment of patients with acquired immune deficiency syndrome(AIDS)-related Burkitt lymphoma(BL).Methods This single-center retrospective cohort study included 41 patients diagnosed with AIDS-related BL at Beijing Ditan Hospital,Capital Medical University,from December 2010 to June 2022.Among them,26 patients received the DA-EPOCH-R regimen(observation group),and 15 patients received the modified CODOX-M/IVAC-R regimen(control group).Clinical characteristics,laboratory findings,toxicities,and treatment outcomes were analyzed.Prognostic risk factors were assessed using a multivariate Cox proportional hazards model.Results Of the 41 enrolled patients,97.6％were male,with a median age of 43 years.The baseline median CD4+cell count was below 200 cells/μL in 41.5％of patients.After a median follow-up of 17 months,the complete response(CR)rate was significantly higher in the observation group compared to the control group(57.7％vs 33.3％).The median overall survival(OS)was also significantly prolonged in the observation group(18.0 months)versus the control group(6.7 months,95％CI:5.0-16.6)(P＜0.001).Treatment-related mortality was notably lower in the observation group(0％vs.26.7％,P＜0.01).Conclusion Compared to the modified CODOX-M/IVAC-R regimen,the DA-EPOCH-R regimen demonstrates superior survival benefits and enhanced safety in the treatment of AIDS-related BL,suggesting it as the preferred chemotherapy option for this patient population.
